Fujifilm to Invest $200 Million to Expand Cell Therapy Development, Manufacturing Capabilities
By Ronnie Harui
Fujifilm plans to invest $200 million in two subsidiaries in the U.S. to expand its global cell therapy contract development and manufacturing capabilities, the Japanese conglomerate said Tuesday.
The investment is earmarked for the new headquarters of Fujifilm Cellular Dynamics in Wisconsin and the California site of Fujifilm Diosynth Biotechnologies, Fujifilm said in a statement. The investment will enable Fujifilm to support the expanding cell therapy market, which is expected to grow by more than 30% a year from an estimated $3.3 billion in fiscal 2022, it added.
Cell therapies are a promising treatment with the ability to augment, repair and replace human biology, including organs, tissues and cells, Fujifilm said.
Write to Ronnie Harui at ronnie.harui@wsj.com
(END) Dow Jones Newswires
December 04, 2023 23:14 ET (04:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now